Literature DB >> 33522410

DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury in male mice.

Ravi Nistala1,2,3, Alex I Meuth2,3,4, Cassandra Smith2,3,5, Jianzhong An1,2,3, Javad Habibi2,3,5, M R Hayden2,3,5, Megan Johnson2,5, Annayya Aroor2,3,5, Adam Whaley-Connell1,2,3, James R Sowers2,3,5,6, Susan C McKarns7, Shawn B Bender3,4,6.   

Abstract

Recent evidence suggests that dipeptidyl peptidase-4 (DPP4) inhibition with saxagliptin (Saxa) is renoprotective under comorbid conditions associated with activation of the renin-angiotensin-aldosterone system (RAAS), such as diabetes, obesity, and hypertension, which confer a high cardiovascular risk. Immune system activation is now recognized as a contributor to RAAS-mediated tissue injury, and, importantly, immunomodulatory effects of DPP4 have been reported. Accordingly, we examined the hypothesis that DPP4 inhibition with Saxa attenuates angiotensin II (ANG II)-induced kidney injury and albuminuria via attenuation of immune activation in the kidney. To this end, male mice were infused with either vehicle or ANG II (1,000 ng/kg/min, s.c.) for 3 wk and received either placebo or Saxa (10 mg/kg/day, p.o.) during the final 2 wk. ANG II infusion increased kidney, but not plasma, DPP4 activity in vivo as well as DPP4 activity in cultured proximal tubule cells. The latter was prevented by angiotensin receptor blockade with olmesartan. Further, ANG II induced hypertension and kidney injury characterized by mesangial expansion, mitochondrial damage, reduced brush border megalin expression, and albuminuria. Saxa inhibited DPP4 activity ∼50% in vivo and attenuated ANG II-mediated kidney injury, independent of blood pressure. Further mechanistic experiments revealed mitigation by Saxa of proinflammatory and profibrotic mediators activated by ANG II in the kidney, including CD8+ T cells, resident macrophages (CD11bhiF4/80loLy6C-), and neutrophils. In addition, Saxa improved ANG II suppressed anti-inflammatory regulatory T cell and T helper 2 lymphocyte activity. Taken together, these results demonstrate, for the first time, blood pressure-independent involvement of renal DPP4 activation contributing to RAAS-dependent kidney injury and immune activation.NEW & NOTEWORTHY This work highlights the role of dipeptidyl peptidase-4 (DPP4) in promoting ANG II-mediated kidney inflammation and injury. Specifically, ANG II infusion in mice led to increases in blood pressure and kidney DPP4 activity, which then led to activation of CD8+ T cells, Ly6C- macrophages, and neutrophils and suppression of anti-inflammatory T helper 2 lymphocytes and regulatory T cells. Collectively, this led to kidney injury, characterized by mesangial expansion, mitochondrial damage, and albuminuria, which were mitigated by DPP4 inhibition independent of blood pressure reduction.

Entities:  

Keywords:  albuminuria; angiotensin II; dipeptidyl peptidase-4 inhibition; immune cells; kidney

Mesh:

Substances:

Year:  2021        PMID: 33522410      PMCID: PMC7988815          DOI: 10.1152/ajprenal.00565.2020

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  81 in total

Review 1.  Immunologic Effects of the Renin-Angiotensin System.

Authors:  Steven D Crowley; Nathan P Rudemiller
Journal:  J Am Soc Nephrol       Date:  2017-02-01       Impact factor: 10.121

Review 2.  Revisiting RAAS blockade in CKD with newer potassium-binding drugs.

Authors:  Panagiotis I Georgianos; Rajiv Agarwal
Journal:  Kidney Int       Date:  2017-12-21       Impact factor: 10.612

3.  AT1 receptor-mediated augmentation of angiotensinogen, oxidative stress, and inflammation in ANG II-salt hypertension.

Authors:  Lucienne S Lara; Michael McCormack; Laura C Semprum-Prieto; Sylvia Shenouda; Dewan S A Majid; Hiroyuki Kobori; L Gabriel Navar; Minolfa C Prieto
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-07

4.  Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.

Authors:  Keizo Kanasaki; Sen Shi; Megumi Kanasaki; Jianhua He; Takako Nagai; Yuka Nakamura; Yasuhito Ishigaki; Munehiro Kitada; Swayam Prakash Srivastava; Daisuke Koya
Journal:  Diabetes       Date:  2014-02-26       Impact factor: 9.461

5.  Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: role of GLP-1 and GLP-1 receptor.

Authors:  Dalia M Abd El Motteleb; Shimaa M Elshazly
Journal:  Eur J Pharmacol       Date:  2013-10-24       Impact factor: 4.432

6.  Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations.

Authors:  Shuei Liong Lin; Ana P Castaño; Brian T Nowlin; Mark L Lupher; Jeremy S Duffield
Journal:  J Immunol       Date:  2009-10-28       Impact factor: 5.422

7.  Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy.

Authors:  Yuliya Sharkovska; Christoph Reichetzeder; Markus Alter; Oleg Tsuprykov; Sebastian Bachmann; Thomas Secher; Thomas Klein; Berthold Hocher
Journal:  J Hypertens       Date:  2014-11       Impact factor: 4.844

8.  Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin.

Authors:  Jian Yang; Jack Campitelli; Gang Hu; Yanhe Lin; Jin Luo; Chun Xue
Journal:  Life Sci       Date:  2007-05-21       Impact factor: 5.037

9.  DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.

Authors:  Markus L Alter; Ina M Ott; Karoline von Websky; Oleg Tsuprykov; Yuliya Sharkovska; Katharina Krause-Relle; Jens Raila; Andrea Henze; Thomas Klein; Berthold Hocher
Journal:  Kidney Blood Press Res       Date:  2012-10-15       Impact factor: 2.687

Review 10.  KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.

Authors:  Lesley A Inker; Brad C Astor; Chester H Fox; Tamara Isakova; James P Lash; Carmen A Peralta; Manjula Kurella Tamura; Harold I Feldman
Journal:  Am J Kidney Dis       Date:  2014-03-16       Impact factor: 8.860

View more
  2 in total

Review 1.  Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment.

Authors:  Ruili Yin; Yongsong Xu; Xin Wang; Longyan Yang; Dong Zhao
Journal:  Molecules       Date:  2022-05-10       Impact factor: 4.927

Review 2.  DPP4 as a Potential Candidate in Cardiovascular Disease.

Authors:  Si-Yu Chen; Xiang-Quan Kong; Ke-Fan Zhang; Shuai Luo; Feng Wang; Jun-Jie Zhang
Journal:  J Inflamm Res       Date:  2022-09-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.